Novo Nordisk receives a positive opinion from the CHMP for a label update of Wegovy to reflect reduced heart failure symptoms ...

Committee for Medicinal Products for Human Use (CHMP) has recommended an update to Novo Nordisk’s Wegovy (semaglutide 2.4 mg) ...

The company noted that Wegovy is the first obesity medication to receive a positive opinion recommending a label update that reflects reduced symptoms and improved physical limitations and exercise ...

Doctors are sending out a warning after children as young as 10 years old are using drugs like Ozempic and Wegovy.

Researchers found that patients with obesity had an average weight loss of 12.9% with semaglutide vs 5.6% with liraglutide ...

While Ozempic and similar medications are all the buzz right now, many of us still aren’t sure what they actually are or how they work! This video breaks down all the essential details to help you ...

Novo Nordisk’s obesity drug Wegovy is now recommended by EU regulatory authorities for obesity-related heart conditions.

U.S. telehealth company Hims & Hers Health on Wednesday said it will sell compounded versions of Novo Nordisk's popular ...

Three doctors have expressed concerns to Newsweek about weight loss drugs for children, with research suggesting an initial reluctance to prescribe them.

In the heavyweight title match between weight loss meds, we have ourselves a victor.In the battle between Novo Nordisk’s ...

Novo Nordisk A/S's shares have stalled recently, but this looks like a natural digestion of gains from prior years. Click for ...

The European Medicines Agency backed the use of Novo Nordisk's popular drug Wegovy to help ease heart failure in people with ...